Company: GANX
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001558370-25-003823
Chunk: 7

Company: Gain Therapeutics, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 7
---
 enrollment for our trials or slower commercial revenue if approved, and we may also face enrollment challenges as a result of other factors;

oour product candidates are novel and still in development. If we are unable to successfully develop, receive regulatory approval for and commercialize our current or future product candidates, our business will be harmed;

owe  have started testing one of our product candidates in clinical trials. Success in preclinical studies or clinical trials may not be indicative of results obtained in later clinical trials;

oclinical trials required for our product candidates are expensive and time-consuming, and their outcomes are uncertain;

owe will need to raise additional capital, which may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. Additional capital may not be available on favorable terms or at all which may force us to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations;

owe are subject to extensive and costly government regulations which are subject to change;